首页> 外文期刊>Virology Journal >HPV genotype determination and E6/E7 mRNA detection for management of HPV positive women
【24h】

HPV genotype determination and E6/E7 mRNA detection for management of HPV positive women

机译:HPV基因型测定和E6 / E7 mRNA检测可治疗HPV阳性女性

获取原文
       

摘要

Clinical management of HPV positive women is difficult since many of the infections, including high-risk oncogene genotypes (hr-HPV), are transient. Therefore only a limited number of patients have a high-grade lesion and sending all HPV positive women for colposcopy would only increase costs and unnecessary treatment, with serious psychological consequences for patients. The need has emerged to identify other HPV related markers able to correctly detect women with a high-risk of developing high-grade lesions. Genotyping and the search for E6/E7 mRNA are among the possible candidates. The study was carried out by means of an observational analysis of the data relative to 674 HR-HPV positive women who we had observed from January 2013 to June 2015; the data had been gathered in a database at the HPV Center of the University Hospital of Catania, Italy. Women were considered eligible for this study if the following data was present in the database: Pap TEST, histologic evaluation, HPV TEST and E6/E7 mRNA detection. We calculated the Odds Ratio (OR) of woman who were mRNA positive, with CIN2+ lesions, and Odds Ratio of HPV16 positive women. Transcripts were detected in 23.6% (69/292) of the women with CIN1 and in 97.2% (210/220) of those with CIN2?+?. Regarding genotyping, the 81,8% (180/220) of the women with CIN2+ had genotype 16, while only 18.1% (40/220) had genotype 18, 31, 33, 45. We calculated the OR in the group of HPV16 women with CIN2+ (OR?=?4.62; 95% CI?=?3.13 to 6.82), this value increased (OR?=?106.12; 95% CI?=?53.71 to 209.69) in women with CIN2+ and positive mRNA. The presence of the HPV16 genotype in our study was associated with a risk 5 times greater of developing a high-grade lesion (CIN2+) (OR?=?4.62 95% CI:3.13–6.82); this supports the hypothesis that it would be opportune to have targeted protocols for the management of HPV 16 positive women. The results showed that there was an association between E6/E7 mRNA expression and histology (OR?=?106.12; 95% CI?=?53.71 to 209.69). The E6/E7 mRNA test showed a higher prevalence of E6 and E7 transcripts in patients with higher-grade lesions. The results of this study suggest that the HPV genotype determination and E6/E7 mRNA detection would find an important application for management of HPV positive women.
机译:HPV阳性妇女的临床管理很困难,因为许多感染都是短暂的,包括高危癌基因型(hr-HPV)。因此,只有少数患者具有高度病变,将所有HPV阳性的妇女送往阴道镜检查只会增加费用和不必要的治疗,对患者造成严重的心理后果。迫切需要鉴定其他HPV相关标志物,以能够正确检测出具有高度发展性高病变风险的女性。基因分型和寻找E6 / E7 mRNA都是可能的候选方法。该研究是通过对我们从2013年1月至2015年6月观察到的674例HR-HPV阳性女性的相关数据进行观察性分析而进行的;数据已收集在意大利卡塔尼亚大学医院HPV中心的数据库中。如果数据库中包含以下数据,则认为女性符合这项研究的条件:Pap TEST,组织学评估,HPV TEST和E6 / E7 mRNA检测。我们计算了具有CIN2 +病变,mRNA阳性的女性的几率(OR)和HPV16阳性的女性的几率。在CIN1妇女中,有23.6%(69/292)的女性和CIN2α+β妇女中有97.2%(210/220)的女性有转录本。在基因分型方面,患有CIN2 +的女性中有81.8%(180/220)具有基因型16,而只有18.1%(40/220)具有基因型18、31、33、45。我们计算了HPV16组的OR患有CIN2 +且mRNA阳性的女性(OR?=?4.62; 95%CI?=?3.13至6.82),该值增加(OR?=?106.12; 95%CI?=?53.71至209.69)。在我们的研究中,HPV16基因型的存在与发生高级别病变(CIN2 +)的风险相比高5倍(OR?=?4.62 95%CI:3.13-6.82);这支持了以下假设:针对HPV 16阳性女性进行针对性的治疗方案是适当的。结果表明,E6 / E7 mRNA表达与组织学之间存在关联(ORα=≥106.12; 95%CIβ=≥53.71至209.69)。 E6 / E7 mRNA测试显示,病灶级别较高的患者中E6和E7转录本的患病率较高。这项研究的结果表明,HPV基因型的确定和E6 / E7 mRNA的检测将在管理HPV阳性妇女中找到重要的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号